ePT--the Electronic Newsletter of Pharmaceutical Technology, Jul 14, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Jul 14, 2011
News
FDA Introduces Strategy to Combat Food Smuggling
By Angie Drakulich
FDA announced in early July 2011 that it has made progress toward implementing the US Food Safety Modernization Act, which was enacted in January of this year.
SOCMA Offers Support for Free Trade Pacts with South Korea, Panama, and Colombia
By Patricia Van Arnum
SOCMA has issued its support this week of the passage of pending free-trade agreements with South Korea, Panama, and Colombia by two Congressional committees.
FDA Bans Import of Drugs from Dr. Reddy's Mexico Site
By Erik Greb
FDA banned the importation of products manufactured at the Mexican unit of Dr. Reddy's Laboratories. The import ban is a result of the company's failure to correct the violations listed in a recent Warning Letter to the agency's satisfaction.
The Economic Contribution of the US Biopharmaceutical Industry
By Amy Ritter
Recent trends in the US biopharmaceutical industry suggest this is a pivotal area for potential job creation.
EMA Plans Public Access to Side-Effects Data
By Stephanie Sutton
Members of the public will soon be able to access data in the EudraVigilance database—EMA's central repository for reports of suspected adverse reactions related to authorized medicines in the European Economic Area.
Week of July 11, 2011: UPS and Merck Extend Distribution and Logistics Agreement; Merck Serono Makes Two Executive Management Team Appointments; and More.
Sanofi Forms Research Pact with Weill Cornell Medical Center; Steven A. Nichtberger Resigns as President and CEO of Tengion; and More.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here